New generation in femtosecond lasers

Article

Dr. J. Stevens, UK.

At the opening of the ESCRS 2010 Convention in Paris, France, Ziemer Group unveiled its new generation of Femtosecond Surgical Lasers. Based on the experience from over half a million Z-LASIK procedures, Ziemer engineers have developed a new laser with a pulse rate of more than five million pulses per second.

The Crystal-tuned, wavefront-optimized, high numerical aperture optics focuses the laser beam on an extremely small tissue volume of less than 2 microns across, achieving smooth tissue dissection at just a few nano-Joules of Laser pulse energy. Ziemer's Crystal-tuned laser technology aims to achieve crystal-perfect tissue dissection with minimal thermal effects, minimum trauma, and minimum oedema in the corneal tissue. This permits dissecting stromal tissue close to Bowman's membrane or the Descemet, without inflicting damage on epithelium or endothelium.

Surgeons who have been using the Ziemer FEMTO LDV have been marketing their LASIK procedures successfully under the name Z-LASIK. Procedures performed with the new Crystal Line platform will be marketed under the trade name Z-LASIK Crystal Plus.

More precise, more uniform flap thickness minimizes risk in thin-flap (SBK) procedures; and shortest procedure times help avoid oedema and enhance predictability of refractive ablation. A new proprietary, smooth in-plane circular rim cut creates a self-sealing flap border that avoids in-growth and facilitates flap lifting.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.